Drug makers update effort to reinstate Tysabri

Share this article:
Biogen Idec and Elan said that their efforts to reinstate multiple sclerosis drug Tysabri may turn a corner shortly.
The companies said their safety review of Tysabri (natalizumab) in Crohn's disease and rheumatoid arthritis should be completed "in the coming weeks," following which they plan on submitting a supplemental Biologics License Application to the FDA for the drug in MS.
A safety evaluation of Tysabri in MS, completed in August, resulted in no new confirmed cases of progressive multifocal leukoencephalopathy (PML).
As first reported in the Associated Press, Biogen Idec CEO James Mullen said he would recommend that Tysabri's label carry warnings about three previously reported cases of PML, discovered after clinical trials, and a warning that patients with weak immune systems are more susceptible to it.
The three cases of PML, two of which were fatal, led Biogen Idec and Elan to withdraw Tysabri from the U.S. market in February and suspend clinical trials of the drug. Scientists still don't fully understand how Tysabri may have enhanced those patients' risk for contracting the rare demyelinating disease of the central nervous system.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...